IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hopf, Carsten Confirmation No.: 1220

Serial No.: 10/570,909 Art Unit: 1633

Filed: March 29, 2006 Examiner: Hill, Kevin Kai

Customer No.: 21559

Title: TREATMENT OF NEURODEGENERATIVE DISEASES

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REPLY TO NOTICE OF ALLOWANCE

In reply to the Notice of Allowance that was mailed in connection with the abovecaptioned application on December 22, 2009 and having confirmation number 1220, enclosed are:

A completed fee transmittal form PTOL-85; and

Payment in the amount of \$1810.00 to cover the issue fee required by 37 C.F.R. § 1.18(a) of \$1510.00, the publication fee of 300.00.

If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted

Date: 1 Junh 6, 2010

Kristina Bieker-Brady, Ph.D.

/Reg./No/39/10

101 Federal Street Boston, MA 02110 Telephone: 617-428-0200 Facsimile: 617-428-7045

Clark & Elbing LLP

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 or Fax (571)-273-2885

CURRENT CORRESPONDENCE ADDRESS (Note: 11se Block 1 for any change of address)

12/22/2009

RESTRUCTIONS: This form should be used for transmitting the ISSUE FIEE and FIELL/CATION FIEE (if required). Block 1 Investige 5, should be comprised where restricts all interfer comproseders reducing the Financian America orders not destructed compressing or should be conventioned and the association of the compression conventions defines a substantial unless conjected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; nat/or (b) indicating a separate "FEE ADDRESS" for ministructure for conflictations. Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

21559 2590 CLARK & FLBING LLP 101 FEDERAL STREET BOSTON, MA 02110

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Potals Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being factimal transmitted to the USFTO (37) 127-2285, on the site indicated between the Company of the Compa

							(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.		CONFIRMATION NO.
10/570,909 03/29/2006 TITLE OF INVENTION: TREATMENT OF NEURODEGENERATIVE			Carsten Hopf DISEASES		50125/147001 1220		1220
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSU	B FEE	TOTAL FEE(S) DUE	DATEDUE
nonprovisional	NO	\$1510	\$300	\$0		\$1810	03/22/2010
ЕХЛЬ	INER	ART UNIT	CLASS-SUBCLASS	7			
HILL, KI	VIN KAI	1633	435-004000				
Address form PTO/S:	ondence address (or Cha	(1) the names of up or agents OR, alternal (2) the name of a single registered attorney or	E. For gistaling on the patent froot page, list 1) the annes of up to 3 registered patent attorneys a agent OR, alternatively, 2) the name of a night from (having as a member a septietered attorney or agent) and the names of up to septietered attorney or agent) and the names of up to septietered attorney or agent) and the names of up to septietered attorney or agent) and the names of up to septietered attorney or agent and the names of up to septietere				
PLEASE NOTE: Unless an analogue is identified below, so assigned data will appear on the patent. If an assignee is identified below, the document has been file recordation as set forth in 37 URS 3.11. Completion of the form is NOT a subtractive fill find an alignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) Cellzome AG Heidelberg Germany Please check the assocrative assignee category or cuterosise (will not be tristed on the outcom): Individual Of Composition or other orivate group estive I Govern							
	o small entity discount p	Reymont of Fec(s): (Please first reapply only previously paid issue fee shown above) A check is enclosed. Payment by credit card. Form PTO-2035 is attached. The Direct is teached such graph of the propriet fee(s), any defliciency, or credit any overpayment, to Deposit Account Number (33:2095 (enclose an extra copy of this form).					
a. Applicant claim	SMALL ENTITY state	s. See 37 CFR 1.27.	b. Applicant is no lo d from anyone other than Office.				R 1.27(g)(2).
Authorized Signature	Kristina Bick	er-Brady, Ph.D.		Date Registration N	w/4 1039,	8, 757 0 109	by the USPTO to process) g gathering, preparing, and he you require to complete turnent of Commerce, P.O. or Patents, P.O. Box 1450,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT ATTORNEY DOCKET NO. 50125/147001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Hopf, Carsten

Confirmation No.: 1220

Serial No.:

10/570,909

Art Unit:

1633

Filed:

Title:

March 29, 2006

Examiner:

Hill. Kevin Kai

Customer No.:

March 29, 2006

: 21559

TREATMENT OF NEURODEGENERATIVE DISEASES

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

In reply to the Notice of Allowance that was mailed in connection with the abovecaptioned application on December 22, 2009 applicant submits the following remarks.

Under the heading "Allowable Subject Matter," the Office states "[t]he specification supports the use of test compounds that decrease FADS activity which consequently inhibits gamma secretase activity to achieve the reduced production of Abeta-42." Applicant notes the specification also supports methods of identifying inhibitors of Abeta-42 formation by determining if a test compound binds to functionally active FADS2 and determining whether this test compound inhibits gamma secretase activity to reduce Abeta-42 formation.

If there are any additional charges or any credits, please apply them to Deposit

Account No. 03-2095.

Date: MWAB, 2010

Respectfully submitted

Kristina Bijeker-Brady, Ph.D.

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045